Back to results
US 9,427,441 B2Granted
Targeting primary cilia to treat glaucoma
AssigneeIndiana University Research and Technology Corporation
InventorYang Sun
Life of this patent
Estimating the term…
Abstract
Methods for reducing intraocular pressure and treating glaucoma are disclosed. The methods include administering to an individual a composition comprising a TRPV4 agonist.
Claims13
A method for reducing intraocular pressure in an individual in need thereof, the method comprising:
- administering a composition comprising a transient receptor potential cation channel subfamily V member 4 (TRPV4) agonist to the individual, wherein the TRPV4 agonist is (N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide).
A method for treating glaucoma in an individual in need thereof, the method comprising:
- administering a composition comprising a transient receptor potential cation channel subfamily V member 4 (TRPV4) agonist to the individual, wherein the TRPV4 agonist is (N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide).
A method for treating a ciliopathy in an individual in need thereof, the method comprising:
- administering a composition comprising a TRPV4 agonist to the Individual, wherein the TRPV4 agonist is (N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide).
Dependencies are inferred from the claim text.